Comprehensive clinicopathological and genomic profiling of gallbladder cancer reveals actionable targets in half of patients
Tessa J.J. de Bitter(Radboud University Nijmegen), Rachel S. van der Post(Radboud University Nijmegen), Erik A. M. Jansen(Radboud University Nijmegen), Marjolijn J. L. Ligtenberg(Radboud University Nijmegen), Carla M.L. van Herpen(Radboud University Nijmegen), Leonie I. Kroeze(Radboud University Nijmegen), Joanne Verheij, Irıs D. Nagtegaal(Radboud University Nijmegen), Shannon van Vliet(Radboud University Nijmegen), Elise A. J. de Savornin Lohman(Radboud University Nijmegen), M. Elisa Vink-Börger(Radboud University Nijmegen), Femke Simmer(Radboud University Nijmegen), Philip R. de Reuver(Radboud University Nijmegen), Daniel von Rhein(Radboud University Nijmegen)
Cited by 41
Related Papers
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1
|Nature Genetics|2008|818
Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial
|The Lancet. Gastroenterology & hepatology|2019|597
Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline <i>CDH1</i> mutation carriers
|Journal of Medical Genetics|2015|567